Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pet Pharm Biotech CoROCO:7762 -2.65%26 EV-to-EBIT is 94.95 as of Sep. 15, 2026, which is 26% below its 10-year median of 128.45. GuruFocus rates ROCO:7762 with a GF Score™ of 26/100. The stock has 5 warning signs investors should review. Among 684 Drug Manufacturers companies, Pet Pharm Biotech Co ranks worse than 93.71% on this metric.
Pet Pharm Biotech Co (ROCO:7762) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Pet Pharm Biotech Co's Enterprise Value for the quarter that ended in Jun. 2026 was NT$2,599.8 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Pet Pharm Biotech Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was NT$30.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pet Pharm Biotech Co EV-to-EBIT Related Terms
Pet Pharm Biotech Co EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Pet Pharm Biotech Co's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:7762 vs LLY, JNJ, ABBV: EV-to-EBIT Comparison
For the Drug Manufacturers - General subindustry, Pet Pharm Biotech Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pet Pharm Biotech Co EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Pet Pharm Biotech Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Pet Pharm Biotech Co's EV-to-EBIT falls into.
Pet Pharm Biotech Co's current Enterprise Value is NT$2,893.1 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Pet Pharm Biotech Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was NT$30.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pet Pharm Biotech Co (ROCO:7762) has a EV-to-EBIT of 94.95 as of Sep. 15, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Pet Pharm Biotech Co and its competitors. This is 26% below median its historical median of 128.45. Over the past decade, Pet Pharm Biotech Co's EV-to-EBIT has ranged from 66.86 to 260.64. According to the industry distribution chart, Pet Pharm Biotech Co ranks #641 out of 684 companies in the Drug Manufacturers industry, placing it in the top 93.7%.
Is Pet Pharm Biotech Co's EV-to-EBIT too high?
Pet Pharm Biotech Co's current EV-to-EBIT of 94.95 is 26% below median its 10-year median of 128.45. Over the past 10 years, this metric has ranged from a low of 66.86 to a high of 260.64. The Drug Manufacturers industry median EV-to-EBIT is 15.84. Pet Pharm Biotech Co's value of 94.95 is 499.4% above this industry median. Based on the distribution chart, Pet Pharm Biotech Co ranks #641 out of 684 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Pet Pharm Biotech Co has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Pet Pharm Biotech Co's EV-to-EBIT compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Pet Pharm Biotech Co ranks #641 out of 684 companies for EV-to-EBIT. This places Pet Pharm Biotech Co in the lower half of its industry. The industry median EV-to-EBIT is 15.84. Pet Pharm Biotech Co's value of 94.95 is 499.4% above this benchmark. Historically, Pet Pharm Biotech Co's own EV-to-EBIT has ranged from 66.86 to 260.64 over the past decade. While the company's 10-year median is 128.45 vs. the industry median of 15.84, Pet Pharm Biotech Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.84, based on 684 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pet Pharm Biotech Co's current EV-to-EBIT of 94.95 is 499.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Pet Pharm Biotech Co and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pet Pharm Biotech Co's current EV-to-EBIT is 94.95, which is 26% below median its own 10-year median of 128.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pet Pharm Biotech Co stock overvalued right now?
Pet Pharm Biotech Co (ROCO:7762) has a current EV-to-EBIT of 94.95. The current EV-to-EBIT is 94.95, which is 26% below median its 10-year median of 128.45 and 499.4% above the Drug Manufacturers industry median of 15.84. Pet Pharm Biotech Co's overall GF Score™ is 26/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Pet Pharm Biotech Co (ROCO:7762), the current EV-to-EBIT is 94.95 as of Sep. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Pet Pharm Biotech Co Ltd is a Pharmaceutical company. The company is engaged in manufacturing medicinal products and medicine drugs. The products offered by the company include FDG Fluodeoxyglucose Injection (18F-FDG), Naolixi Injection (18F-FBB), Sodium fluoride injection (18F-NaF), and others.
26GF Score
Get the complete analysis for ROCO:7762
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7762 has been successfully added to your 
